Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Beneficial effect of autologous blood transfusion on infectious complications after colorectalcancer surgery. Homologous blood transfusion has been associated with an increased risk of postoperative infectious complications. To test the clinical consequences of this apparently immunosuppressive effect of homologous blood in a controlled trial, we designed a study in which the control group deposited autologous blood before their operations for use should transfusion be needed. We enrolled 120 (...) patients with apparently curable colorectalcancer who were able to predeposit autologous blood (haemoglobin > 12.5 g/dL). 62 patients were assigned to receive homologous blood if blood transfusions were needed during operation, and the other 58 to receive their own predeposited blood followed, if necessary, by homologous blood [corrected]. Despite the similarity between the groups in factors known to affect the risk of postoperative infections, there was a significant difference in postoperative
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectalcancer. To compare the length of survival and quality of life in patients given combination chemotherapy in addition to supportive care and in patients given only supportive care.Randomised study.Gastrointestinal oncology departments.40 previously untreated patients with histologically confirmed, measurable colorectalcancer that was locally recurrent (...) this sample of patients with disseminated colorectalcancer the chemotherapy regimen was an effective form of palliative treatment.
Filtering strategies in mass population screening for colorectalcancer: an economic evaluation Filtering strategies in mass population screening for colorectalcancer: an economic evaluation Filtering strategies in mass population screening for colorectalcancer: an economic evaluation Walker A, Whynes D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of mass population filtering strategies for the selection of individuals requiring further screening (colonoscopic investigation) for the detection of colorectalcancer (CRC). The strategies examined were as follows. Strategy 1: the Hemoccult faecal occult blood (FOB) test. A 3-day test, with no subsequent retesting of positives or negatives. Strategy 2: the Hemoccult
Randomised, controlled trial of faecal occult blood screening for colorectalcancer. Results for first 107,349 subjects. To assess the effectiveness of screening by faecal occult blood tests, 107,349 people without symptoms of colorectal disease identified from general practitioner records have been randomly allocated to test and control groups. 53,464 test subjects were invited to carry out the screening test; 27,651 (53%) of the 52,258 who received the tests did so. Further investigation (...) A) was 0.72 per 1000 person-years. Cancers detected by screening were at a less advanced pathological stage, but it is too early to show any effect of screening on mortality from colorectalcancer.
Controlled trial of faecal occult blood testing in the detection of colorectalcancer. 20 525 patients from general practitioners' lists were randomly allocated into test and control groups. The 10 253 test subjects were invited to perform haemoccult faecal occult blood testing over 3 days. 3613 (36 . 8%) of the 9807 who received their invitations completed the test. Compliance was improved by direct invitation from the general practitioner and by prior health education by letter or interview
Prolongation of postoperative disease-free interval and survival in human colorectalcancer by B.C.G. or B.C.G. plus 5-fluorouracil. 83 patients with colorectal carcinoma of the Dukes' C class were randomised to receive postoperative adjuvant therapy with B.C.G. alone or in combination with oral doses of 5-fluorouracil (5-F.U.), and have been followed for up to thirty months. Results were compared with carefully selected historical controls who were treated by surgery alone. A statistically (...) 0.04) and ineffective (as yet) among 23 patients with 5 or less positive lymph-nodes. These results suggest that adjuvant immunotherapy, with or without chemotherapy, can improve the prognosis of surgically treated patients with colorectal carcinoma of the Dukes' C class.